Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15867786 | 0.81 | DGAT1 (0.34) | DGAT1MAPK1 | |
| SCHEMBL15722040 | 0.79 | MAPK1 (0.33) | DGAT1MAPK1 | |
| SCHEMBL15867790 | 0.76 | CHRM2 (0.37) | DGAT1 | |
| SCHEMBL15867791 | 0.76 | CHRM2 (0.37) | DGAT1 | |
| SCHEMBL15867793 | 0.73 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL15867796 | 0.69 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL1700824 | 0.69 | FFAR3 (0.33) | MAPK1 | |
| SCHEMBL24515274 | 0.69 | DGAT1 (0.32) | DGAT1MAPK1 | |
| SCHEMBL5663490 | 0.68 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL26704578 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107219-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107219-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9567330-B2 | Azabenzimidazole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567330-B2 | Azabenzimidazole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20140194420-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20140194420-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107219-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAB1, PRKAB2, PRKAG1 | DGAT1 3436/4885MAPK1 706/4885 |
| US-20140194420-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAB1, PRKAB2, PRKAG1 | DGAT1 3436/4885MAPK1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.